Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067144 · ClinicalTrials.gov registry record · Phase 3
Stanford Accelerated Recovery Trial (START)
A Phase 3 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
NCT01067144: Clinical Trial Phase 3 study, sponsored by Stanford University.
NCT01067144 is a Phase 3 study that was terminated before completion, run by Stanford University. The registered enrollment target is 422 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01067144, a Phase 3 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.
Interventions
- DRUG Gabapentin
- DRUG Lorazepam (active control)
- DRUG Placebo (inactive)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2010-05 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067144
The ClinicalTrials.gov registry entry for NCT01067144 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gabapentin is the first listed.
NCT01067144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01067144 about?
NCT01067144 is a clinical study titled "Stanford Accelerated Recovery Trial (START)". The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain...
What is the current status of trial NCT01067144?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2010-05. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01067144?
The interventions under investigation include: Gabapentin (DRUG), Lorazepam (active control) (DRUG), Placebo (inactive) (DRUG).
Who is sponsoring clinical trial NCT01067144?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.